|Articles|August 1, 2008

August 2008
Volume 14
Issue 8

Participant Disclosure (Am J Manag Care. 2008;14[suppl 8]:S241-S268)

Our July 2008 supplement on Biologics and Benefit Design, funded by Amgen Inc, (Am J Manag Care. 2008;14[suppl 8]:S241-S268), included an error of omission on the Participant Disclosures page.

The following disclosures for Robert Berglund should have been noted on S244:

Robert Berglund

Honoraria, Amgen Inc

Download PDF: Participant Disclosure (Am J Manag Care. 2008;14[suppl 8]:S241-S268)

Articles in this issue

about 18 years ago

Article

Agreement Between Patient-reported Symptoms and Their Documentation in the Medical Record

about 18 years ago

Article

A Meta-analysis Update: Percutaneous Coronary Interventions

about 18 years ago

Article

Managed Care Enrollment and Chronically Disabled Women With Breast Cancer

about 18 years ago

Article

Medicare HMO Impact on Utilization at the End of Life

about 18 years ago

Article

Strategies for Identifying and Channeling Patients for Depression Care Management

about 18 years ago

Article

Flunking Asthma? When HEDIS Takes the ACT

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

Participant Disclosure (Am J Manag Care. 2008;14[suppl 8]:S241-S268)

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About the FDA's Peptide Reversal

US Employer Health Care Costs Projected to Rise 9.5% in 2027

Student Mental Health, Success Tied to Future Health and Affordability

FDA Approves First Orexin Agonist for Narcolepsy Type 1

Rural Patients Face Gaps in Hospice Access, Care Intensity